FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of…
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study…